| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -209,130 | -47,210 | 0 | 0 | 0 |
| Net Income Growth | -342.98% | unch | unch | unch | unch |
Metsera Inc (MTSR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Metsera Inc. is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight and related conditions. Metsera Inc. is based in NEW YORK.
Fiscal Year End Date: 12/31